A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

@article{Mok2009AGS,
  title={A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.},
  author={S. Mok and T. Bonome and V. Vathipadiekal and A. Bell and Michael E. Johnson and K. Wong and D. Park and Ke Hao and D. K. Yip and H. Donninger and L. Ozbun and G. Samimi and J. Brady and Mike Randonovich and C. Pise-Masison and J. Barrett and W. Wong and W. Welch and R. Berkowitz and M. Birrer},
  journal={Cancer cell},
  year={2009},
  volume={16 6},
  pages={
          521-32
        }
}
Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissected serous ovarian tumors. Independent evaluation confirmed the association of a prognostic gene microfibril-associated glycoprotein 2 (MAGP2) with poor prognosis, whereas in vitro… Expand
A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis
TLDR
MAGP2 is a multifunctional secreted protein—important for elastic microfibril assembly and modulating endothelial cell behavior—with a newly identified role in cell survival, providing a potential mechanistic link between MAGP2 and angiogenesis as well as patient survival. Expand
CANCER ASSOCIATED FIBROBLAST DERIVED ANGIOGENIC FACTOR MFAP5 IN OVARIAN CANCER PROGRESSION
TLDR
The functional roles and mechanisms by which stromal MFAP5 modulates ovarian tumor progression and angiogenesis are delineated and the potential of targetingStromalMFAP5 as therapy for ovarian cancer is investigated. Expand
Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer
TLDR
The established risk score can quantify the prognosis of ovarian cancer patients more accurately and is able to predict the putative biological response of cancer samples to a programmed death ligand 1 blocking immunotherapy, which could be useful for future clinical studies on immunotherapy in ovarian cancer. Expand
FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.
TLDR
It is shown that FGF18 signaling promoted tumor progression by modulating the ovarian tumor aggressiveness and microenvironment and may serve as a therapeutic target for a subset of ovarian cancers. Expand
Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
TLDR
Thirty-one angiogenic-related genes were associated with survival in advanced HGSC and nine of these genes were confirmed in independent publicly available databases. Expand
Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance
TLDR
It is identified that CENPK was specifically upregulated in ovarian cancer cells and can be used as a novel tumor marker of ovarian cancer. Expand
An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients.
TLDR
A more comprehensive methylomics of cell adhesion molecules is needed and may advance personalized treatment with adhesion molecule-related drugs. Expand
Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
TLDR
An 11-gene signature is revealed that allows a more precise prognosis for patients with serous cancer of the ovary treated with carboplatin- and paclitaxel-based therapy and offers opportunities for new therapies to improve clinical outcome in ovarian cancer. Expand
Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer
TLDR
Complete transcriptional profiling on 129 advanced stage, high grade serous ovarian cancers was performed and the corresponding “angiogenesis signature” was validated in ten published independent ovarian cancer gene expression datasets and is significantly associated with overall survival. Expand
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.
TLDR
Evidence is provided to support that differential gene methylation status is associated with elevated expression of AKAP12 in taxol-resistant ovarian cancer cells and ovarian cancer patient subsets, and elevated AKAP 12 transcript expression is a poor prognostic and predictive marker for progression-free and overall survival in SOC patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
TLDR
The OCPP is an independent prognostic determinant of outcome in EOC and may ultimately permit identification of EOC patients appropriate for investigational treatment approaches, based on a low likelihood of achieving prolonged survival with standard first-line platinum-based therapy. Expand
Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance
TLDR
Hierarchical clustering and binary tree prediction analysis revealed increased heterogeneity among mucinous tumors compared with their serous counterparts and genes involved in cytoskeletal regulation were specifically up-regulated in the mucinous adenocarcinomas. Expand
Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers
TLDR
Many of the genes that determine ovarian cancer survival are associated with the immune response, suggesting that immune function influences ovarian cancer virulence. Expand
Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers
TLDR
Differences in survival of advanced ovarian cancers are reflected by distinct patterns of gene expression, and the finding that early-stage cancers share expression patterns with the advanced stage long-term survivors, suggesting a shared favorable biology. Expand
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
TLDR
The expression profiles of LMP, low-grade, and high- grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low- grade cancers. Expand
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
TLDR
Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups. Expand
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
TLDR
Amplification of FGF-1 at 5q31 in ovarian cancer tissues leads to increased angiogenesis, and autocrine stimulation of cancer cells, which may result in poorer overall survival in patents with high-grade advanced stage serous ovarian cancer. Expand
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
TLDR
It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour. Expand
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment.
TLDR
It is hoped that clinicians will continue to encourage patients to participate in randomized clinical trials so that optimal therapy for early ovarian cancer can be established. Expand
Altered adhesion properties and alpha v integrin expression in a cisplatin‐resistant human ovarian carcinoma cell line
TLDR
The growth of I GROV1‐R10 cells, but not of IGROV1 cells, was partly inhibited by a specific αvβ5‐blocking antibody suggesting that αv β5 integrin contributed to IGRov1‐ R10 cell proliferation. Expand
...
1
2
3
...